BioSpace News Archive

First Quarter Net Loss from Continuing Operations of $72.7 Million, or $1.36 Per Share, Compared to the Prior Year First Quarter Net Loss of $99.3 Million, or $1.88 Per Share

Moleculin Biotech, Inc., a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, announced a presentation at the AACR Annual Meeting held from June 22nd-24th, 2020, illustrating a unique approach to creating drugs capable of reaching tumors hiding in organs where existing anticancer drugs cannot accumulate in therapeutic concentrations.

Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2020 Financial Results on August 10, 2020

Moderna, Inc. and Catalent, Inc. announced a collaboration for large-scale, commercial fill-finish manufacturing of Moderna’s mRNA-based COVID-19 vaccine candidate at Catalent’s biologics facility in Bloomington, Indiana.

Intensity Therapeutics, Inc. , a clinical-stage biotechnology company pioneering a novel, immune-based drug approach to treat solid tumor cancers through direct tumor injection, today announced the publication of results from the Company’s nonclinical research in the International Journal of Molecular Sciences (IJ

AIV001 was shown to be safe and well tolerated after local intradermal treatment of incisional wounds Reduction in fibrosis was observed from single AIV001 treatment post-wounding NEWPORT BEACH, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- AiViva Biopharma Inc., a clinical-stage biotechnology company developing innovative therapies to address major unmet medical needs, today announced completion of its first Phase 1/2a study evaluating AIV001 in dermal scarring. A total of 16 subjects who

Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced the initiation of a Phase 2 trial of its potent, second-generation core inhibitor, ABI-H2158 (2158). The international multi-center, randomized, placebo-controlled trial will evaluate 2158 with entecavir versus placebo with

Next-Generation Technology Makes Percept™ the First and Only DBS System with Ability to Capture Patient-Specific Brain Signals for More Personalized, Data-Driven Treatment DUBLIN, June 25, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announces it received Food and Drug Administration (FDA) approval for the Percept™ PC Deep Brain Stimulation (DBS) system. BrainSense™ technology makes Percept the first and only DBS neurostimulation sys

Emmaus Life Sciences, Inc. (OTCQB: EMMA) , a leader in sickle cell disease treatment, today reported that on June 22, 2020 the National institutes of Health (NIH) issued a Notice that the National Cancer Institute, an institute of the NIH, Department of Health and Human Services, is contemplating the grant to Emmaus Medical, Inc., a subsidiary of Emmaus Life Sciences, Inc., of an Exclusive Patent License to practice the inventions embodied i

Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases, today announced that the company is set to join the small cap Russell 2000® Index and the broad-market Russell 3000® Index at the conclusion of this year’s reconstitution of the Russell stock indexes